Literature DB >> 24335721

The Correlation Between Restoration of Lumbar Lordosis and Surgical Outcome in the Treatment of Low-grade Lumbar Degenerative Spondylolisthesis With Spinal Fusion.

Hsien-Ta Hsu1, Stephen S Yang, Tzu Yung Chen.   

Abstract

STUDY
DESIGN: Retrospective clinical study.
OBJECTIVE: To investigate the relationship between the restoration of the lumbar lordosis (LL) and the surgical outcome of patients undergoing spinal fusion for low-grade lumbar degenerative spondylolisthesis. SUMMARY OF BACKGROUND DATA: Correlation between low back pain and the loss of LL in the treatment of low-grade lumbar degenerative spondylolisthesis has seldom been reported.
METHODS: Between May 2005 and July 2011, 59 patients with low back pain and neurogenic claudication due to low-grade lumbar degenerative spondylolisthesis underwent spinal decompression and fusion by a senior surgeon. Ten patients were lost to follow-up. The mean age of the remaining 49 patients (10 men and 39 women) was 64.0 years (range, 47-88 y). Patients were categorized on the basis of the spino-pelvic posture: type 1 [pelvic incidence (PI)<45 degrees] (n=12), type 2 (45 degrees≤PI≤60 degrees) (n=24), and type 3 (PI>60 degrees) (n=13). The LL restoration ratio was calculated by the actual LL divided by the predicted LL. The clinical results were evaluated using a visual analogue scale and the Oswestry Disability Index. Postoperative 36-inch spinal films were used to assess the sagittal balance.
RESULTS: The mean follow-up period was 43.2 months (range, 28-62 mo). Forty-eight patients showed significant improvement with respect to visual analogue scale and Oswestry Disability Index regardless of whether the LL was restored higher or lower. Postoperative 36-inch spinal films showed the C7 plumb line to be within an average of 4.4 cm (range, 0.6-5.6 cm) from the posterior-superior corner of the S1 vertebrae.
CONCLUSIONS: Patients with smaller PI tended to be restored higher, and those patients with a larger PI were more likely to be restored lower. For patients with normal sagittal balance, the surgical outcomes in the treatment of low-grade lumbar degenerative spondylolisthesis with spinal fusion are not correlated with restoration of the LL.

Entities:  

Mesh:

Year:  2016        PMID: 24335721     DOI: 10.1097/BSD.0000000000000061

Source DB:  PubMed          Journal:  Clin Spine Surg        ISSN: 2380-0186            Impact factor:   1.876


  5 in total

1.  Correlation between correction of pelvic balance and clinical outcomes in mid- and low-grade adult isthmic spondylolisthesis.

Authors:  Andrzej Maciejczak; Katarzyna Jabłońska-Sudoł
Journal:  Eur Spine J       Date:  2016-10-11       Impact factor: 3.134

2.  Sagittal spinopelvic alignment in 654 degenerative spondylolisthesis.

Authors:  Emmanuelle Ferrero; Mourad Ould-Slimane; Olivier Gille; Pierre Guigui
Journal:  Eur Spine J       Date:  2015-02-05       Impact factor: 3.134

3.  Cervical balance and clinical outcomes in cervical spondylotic myelopathy treated by three-level anterior cervical discectomy and fusion and hybrid cervical surgery: A CONSORT-compliant study with minimum follow-up period of 5 years.

Authors:  Fanqi Meng; Shuai Xu; Yan Liang; Zhenqi Zhu; Kaifeng Wang; Haiying Liu
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

4.  Predictors of Spontaneous Restoration of Lumbar Lordosis after Single-Level Transforaminal Lumbar Interbody Fusion for Degenerative Lumbar Diseases.

Authors:  Shuhei Ohyama; Yasuchika Aoki; Masahiro Inoue; Takayuki Nakajima; Yusuke Sato; Atsuya Watanabe; Hiroshi Takahashi; Go Kubota; Arata Nakajima; Junya Saito; Yawara Eguchi; Sumihisa Orita; Koichi Nakagawa; Seiji Ohtori
Journal:  Spine Surg Relat Res       Date:  2021-02-22

5.  Oblique Lumbar Interbody Fusion with Stand-Alone Cages for the Treatment of Degenerative Lumbar Spondylolisthesis: A Retrospective Study with 1-Year Follow-Up.

Authors:  Yachong Huo; Dalong Yang; Lei Ma; Haidong Wang; Wenyuan Ding; Sidong Yang
Journal:  Pain Res Manag       Date:  2020-01-11       Impact factor: 3.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.